Hemorrhage after thrombolytic therapy for stroke: The clinically relevant number needed to harm

Stroke

Volumn 38, Issue 8, 2007, Pages 2279-2283

  Saver, Jeffrey L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intracerebral hemorrhage; Ischemic stroke; Number needed to treat; Stroke; Thrombolysis

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DECISION MAKING; DISABILITY; FEMALE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE; STROKE; AGE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; EPIDEMIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; RISK FACTOR; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

AGE FACTORS; CAUSALITY; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34548233214     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.487009     Document Type: Article

References (23)

1. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA. 2000;283:2829-2836.
2. Tramer MR, Walder B. Number needed to treat (or harm). World J Surg. 2005;29:576-581.
3. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
4. von Kummer R. Brain hemorrhage after thrombolysis: good or bad? Stroke. 2002;33:1446-1447.
5. Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke. 2007;38:431-440.
6. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke. 2000;31:1429-1438.
7. The NINDS t-PA Stroke Trial Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
8. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
9. Johnston KC, Connors AF Jr, Wagner DP, Haley EC Jr. Risk adjustment effect on stroke clinical trials. Stroke. 2004;35:e43-45.
10. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
11. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005;36:62-65.
12. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066-1070.
13. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 1999;30:1538-1541.
14. Work Group on Thrombolytic Therapy in Stroke. WGoTTi. Position statement of the American Academy of Emergency Medicine on the use of intravenous thrombolytic therapy in the treatment of stroke. 2002. Available at: www.aaem.org/positionstatements/thrombolytictherapy.php. Accessed June 20, 2007.
15. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
16. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880-890.
17. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP; MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-1438.
18. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003;34:e109-137.
19. Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol. 1991;12:1123-1126.
20. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb AP, Lorenzano S, Manelfe C, Bozzao L. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30:2280-2284.
21. NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA for ischemic stroke. Stroke. 1997;28:2109-2118.
22. Qureshi AI, Suarez JI, Yahia AM, Mohammad Y, Uzun G, Suri MF, Zaidat OO, Ayata C, Ali Z, Wityk RJ. Timing of neurologic deterioration in massive middle cerebral artery infarction: a multicenter review. Crit Care Med. 2003;31:272-277.
23. Karepov VG, Gur AY, Bova I, Aronovich BD, Bornstein NM. Strokein-evolution: infarct-inherent mechanisms versus systemic causes. Cerebrovasc Dis. 2006;21:42-46.